LENSAR Inc Overview
Industry: Medical Devices
Sector: Healthcare
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida. LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary Read MoreReported Results
What the company reported, with filing details kept small.
Quarterly result summary
Stored reported-result values did not pass automated reconciliation.
What changed
- Open the SEC source filing while these values are reprocessed.
Source review
Mavefund has withheld unreconciled figures from the public page.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
8-K
May 08, 2026
SEC filing
10-Q
May 08, 2026
SEC filing
10-K/A
Apr 30, 2026
SEC filing
8-K
Mar 31, 2026
Earnings release
Earnings release
Mar 31, 2026
SEC filing
10-K
Mar 31, 2026
SEC filing
10-Q
Nov 06, 2025
SEC filing
8-K
Nov 06, 2025
Earnings release
Earnings release
Nov 06, 2025
SEC filing
10-Q
Aug 07, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
No qualified company news in the last 14 days
No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.